SBIR Phase I: A low-cost, bacterial production platform for the manufacturing of high purity recombinant proteins and growth factors

SBIR 第一阶段：用于制造高纯度重组蛋白和生长因子的低成本细菌生产平台

• 批准号: 2233507
• 负责人: Julie Liang
• 金额: $ 27.5万
• 依托单位: OPERA BIOSCIENCE, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-15 至 2024-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2233507&HistoricalAwards=false
• 关键词: SBIR; Phase; low; cost; bacterial

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to introduce a cost-effective way to produce recombinant proteins and growth factors for the cultivated meat industry. Cultivating animal cells to create animal tissues, including muscle and fat, allows manufacturers to create real animal meat as an alternative to animal-farmed meat. Producing meat in this method may provide a healthier, safer, and more ethical source of real animal meat. This manufacturing process avoids industrial animal farming and consequently uses significantly less land and water. It also avoids the greenhouse gases emitted by industrial animal farming and may emit far fewer greenhouse gases. Cultivated meat could result in a healthier public as well since its controlled production will likely result in fewer foodborne illnesses and avoid the cramped conditions of industrial animal farms that can breed new illnesses. The ability to grow meat in nearly any location increases the nation’s food supply chain resilience and reduces dependence on foreign food imports. Finally, by reducing the amount of industrial animal farms, cultivated meat reduces the need for animal slaughter.The proposed project will demonstrate the ability of the innovation to solve several challenges in the current production of recombinant proteins and growth factors in traditional protein manufacturing platforms that prevent manufacturing at lower costs and with high purity. Cultivated meat has the potential to disrupt the $1 trillion meat industry, but the ability to source high purity, cheap proteins limits the commercial adoption of cultivated meat products. The innovation could produce proteins at cheaper costs than existing platforms because it bypasses expensive and time-consuming operational manufacturing steps while still achieving high purity. The critical technical objectives of this project include: 1) the establishment and comparison of a production benchmark for recombinant growth factor production against the current industry standards, 2) the optimization of the growth conditions necessary for the protein production platform to achieve improved yields, and 3) the creation of a manufacturing platform optimization toolkit to increase the quality and amount of usable protein produced. The knowledge gained at the completion of this project may provide valuable insights into the ability and conditions to promote high production levels of proteins and growth factors while providing data illustrating the improvement when compared against current industry standards.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业创新研究(SBIR)第一阶段项目的更广泛的商业影响是引入一种经济高效的方法来为栽培肉类行业生产重组蛋白质和生长因子。培养动物细胞以产生包括肌肉和脂肪在内的动物组织，使制造商能够创造出真正的动物肉，作为动物饲养肉的替代品。用这种方法生产肉类可能会提供一种更健康、更安全、更符合道德的真正动物肉类来源。这种制造过程避免了工业化的动物饲养，因此使用的土地和水明显更少。它还避免了工业化养殖业排放的温室气体，而且可能排放的温室气体要少得多。养殖肉类也可能带来更健康的公众，因为它的受控生产可能会减少食源性疾病，并避免工业化动物养殖场的狭窄条件，后者可能会滋生新的疾病。几乎在任何地方都可以种植肉类，这提高了该国食品供应链的韧性，减少了对外国食品进口的依赖。最后，通过减少工业化动物养殖场的数量，养殖肉类减少了对动物屠宰的需求。拟议的项目将展示创新的能力，以解决目前传统蛋白质制造平台中重组蛋白和生长因子生产中的几个挑战，这些挑战阻碍了以低成本和高纯度进行制造。培育肉有可能颠覆价值1万亿美元的肉类产业，但无法获得高纯度、廉价的蛋白质，限制了培育肉产品的商业应用。这项创新可以比现有平台更低的成本生产蛋白质，因为它绕过了昂贵和耗时的操作制造步骤，同时仍然获得了高纯度。该项目的关键技术目标包括：1)建立重组生长因子生产的生产基准，并与当前行业标准进行比较；2)优化蛋白质生产平台所需的生长条件，以实现更高的产量；以及3)创建制造平台优化工具包，以提高生产的可用蛋白质的质量和数量。在完成该项目时所获得的知识可能会为促进蛋白质和生长因子的高产量水平的能力和条件提供有价值的见解，同时提供数据说明与当前行业标准相比的改进。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。